PREVALENCE OF NEOPLASIA AT COLONOSCOPY AMONG TESTICULAR CANCER SURVIVORS TREATED WITH PLATINUM-BASED CHEMOTHERAPY

Beatriz Carvalho

UEG Week Copenhagen 2023 | Poster

Colorectal

October 15, 2023

Testicular cancer survivors treated with platinum-based chemotherapy show higher prevalence of colorectal neoplasia at screening colonoscopy compared to average-risk controls in a Dutch multicenter study.

KEY POINTS

- In 137 testicular cancer survivors (median age 50 years), the prevalence of advanced neoplasia was 8.8% compared to 5.5% in 24,193 average-risk American males at primary screening colonoscopy
- After propensity score matching adjusting for age, smoking, alcohol consumption and body mass index, the difference in advanced neoplasia prevalence was larger at 8.7% versus 1.7% ($p<0.0001$)
- Overall prevalence of any neoplasia was significantly higher in testicular cancer survivors (46.0% no lesions) compared to controls (64.5% no lesions, $p<0.0001$)
- Age-stratified analyses showed significant differences in the 40-49, 50-59, and 60-69 year age groups
- The authors conclude the findings support participation in colorectal cancer screening for this population and emphasize clear risk communication

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/e0c04d6c-743b-11ee-82c6-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.